Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix EntrestoⓇ grows +40% in 2021 An essential first-choice treatment in chronic heart failure1 Sales evolution USD m, % cc Ex-US US FY 2.5bn +44% FY 3.5bn +40% 949 924 886 789 716 429 632 569 580 481 519 407 354 318 276 272 520 293 308 314 362 382 405 405 Q1 Q2 Q3 2020 ठ Q4 Q1 Q2 Q3 Q4 2021 C Entresto® AZ K &K L Strong momentum across geographies during 2021 ■ US: Growth across cardiology, primary care Europe: Continued strong growth ■ China: FY strong growth, Q4 impacted by stock compensation in anticipation of NRDL price reductions for HTN listing Confidence in future growth across geographies ■ Further patient uptake in EU and US in heart failure¹ ▪ Launch momentum in HTN¹ in Japan and China HTN Hypertension. NRDL National Reimbursement Drug Listing. 1. Approved indications differ by geography. Examples include "indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with CHF. Benefits are most clearly evident in patients with LVEF below normal." (US) HFrEF (EU) HFrEF and HTN (China and JP). 27 Investor Relations | Q4 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation